Ansell acquires second glove maker

With organic growth in ANN’s HyFlex division remaining stagnate after seeing a 1% move in FY13 rescued by its acquisitions program (which drove revenues up 9%), the company is keen to improve this area.

Comparatively, the sexual wellness division climbed 3% and medical products grew by 4%.

Today’s announcement of a $615 million acquisition of US single-use medical glove maker BarrierSafe is another step in the right direction for the struggling division.  The deal is subject to U.S. anti-trust clearance but is expected to be given the green light, with the sale to be completed by the end of first half of next year. The deal will be structure through a $300 million debt facility and a fully underwritten share purchase plan for A$338 million.

In a statement to the market, ANN’s stated: “BarrierSafe is the leading North American provider of single-use gloves. The acquisition of BarrierSafe is a rare opportunity to strengthen the position of Ansell in the core North American single-use glove market and will further enhance our position as the global leader in hand protection solutions”.

It remains a key part of ANN’s long term strategy that bolt-on business will be key to future success, and with BarrierSafe currently generating US$290 million in revenue, it is expected to be accretive excluding transaction costs and one-off integration costs.

This is the second global acquisition in as many months; in late September ANN brought South Korean-based glove-maker Midas for $40 million. Midas is believed to generate $30 million in revenue turn over and has market presence across the Japanese and South Korean markets.

With the HyFlex glove and plastics division making up 40% of total EBIT, the decline in sale – particularly in Asia and Europe – has been concerning for ANN’s management,  and today’s acquisition continues the current ANN’s mantra of buying its way out of the flat spots.

I see FY14 being a stable year for earnings because revenue is being sourced from the acquisition of other companies, and this method may continue into the future.

IGA, may distribute information/research produced by its respective foreign marketing partners within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.

This information/research prepared by IGA or IGA Group is intended for general circulation. It does not take into account the specific investment objectives, financial situation or particular needs of any particular person. You should take into account your specific investment objectives, financial situation or particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. In addition to the disclaimer above, the information does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. Any views and opinions expressed may be changed without an update.

See important Research Disclaimer.